 FLORHAM PARK, N.J., Dec. 28, 2020 GLOBE NEWSWIRE -- Cellectar Biosciences, Inc. NASDAQ: CLRB, a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced the closing of its previously announced underwritten public offering of its common stock for gross proceeds of approximately 24.5 million at a public offering price of 1.35 per share of common stock, prior to deducting underwriting discounts and commissions and estimated offering expenses. 